Jacobs Levy Equity Management Inc. Has $1.07 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Jacobs Levy Equity Management Inc. lessened its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,397 shares of the company's stock after selling 551,651 shares during the period. Jacobs Levy Equity Management Inc. owned 0.10% of ARS Pharmaceuticals worth $1,070,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of SPRY. KLP Kapitalforvaltning AS bought a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $73,000. BNP Paribas Financial Markets bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at $75,000. Compass Capital Corp MA ADV bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at $106,000. Teacher Retirement System of Texas bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at $122,000. Finally, Freestone Grove Partners LP bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at $132,000. Institutional investors own 68.16% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on SPRY. Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price for the company. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price for the company. Finally, William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $31.00.

ARS Pharmaceuticals Trading Up 1.3%

Shares of SPRY stock traded up $0.19 on Thursday, hitting $14.41. The stock had a trading volume of 175,154 shares, compared to its average volume of 1,238,918. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The firm has a market cap of $1.41 billion, a P/E ratio of -28.35 and a beta of 0.84. The company has a fifty day moving average price of $13.48 and a two-hundred day moving average price of $12.88.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million. On average, analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Insider Activity

In other news, Director Laura Shawver sold 49,600 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the transaction, the director now owns 210,346 shares of the company's stock, valued at $2,357,978.66. The trade was a 19.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Karas sold 10,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now directly owns 7,696 shares of the company's stock, valued at $107,744. This trade represents a 56.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,602 shares of company stock valued at $1,311,041 in the last quarter. Company insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.